China's medical products administrator approved ImmuneOnco Biopharmaceuticals' (HKG:1541) phase 2 trial for its IMM0306 drug for lupus nephritis, according to a Monday filing with the Hong Kong Exchange.
Lupus nephritis is an autoimmune condition which lets the immune system attack its own organs.
The drug binds the cluster of differentiation 47 to CD20, which helps eliminate malignant B cells that help tumor growth, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments